摘要
Abstract
Inflammatory bowel disease(IBD)is a group of chronic nonspecific inflammatory bowel diseases,mainly including Crohn's disease(CD)and ulcerative colitis(UC).The etiology of IBD is not fully understood,but it is thought to be a result of the interaction of multiple factors such as environmental factors,microorganisms,infections,and immune responses in genetically susceptible individuals.Endoscopy and pathology are still commonly used for surveillance,but they are not easily accepted by patients because they are invasive tests,expensive,and the healthcare experience is reduced.Recent studies of noninvasive biomarkers have provided new possibilities for assessing disease status and treatment outcomes in patients with IBD.In this paper,we comprehensively discuss the potential application of noninvasive biomarkers in blood,feces,and body fluids in IBD disease management,especially in reducing invasive testing,optimizing personalized treatment strategies,and identifying disease activity and remission status at an early stage.By integrating the application of these biomarkers with clinical parameters,we can more accurately assess the disease status of the patients,adjust the therapeutic strategies,provide IBD patients with more refined and individualized treatment,and improve the prognosis and quality of life of patients.关键词
炎症性肠病/生物标志物/诊断/粪便钙卫蛋白/微核糖核酸Key words
Inflammatory bowel disease/Biomarkers/Diagnose/Fecal calprotectin/MicroRNA分类
医药卫生
